Edition:
United Kingdom

Recipharm AB (publ) (RECIb.ST)

RECIb.ST on Stockholm Stock Exchange

129.80SEK
18 May 2018
Change (% chg)

3.20kr (+2.53%)
Prev Close
126.60kr
Open
127.20kr
Day's High
130.40kr
Day's Low
124.40kr
Volume
126,668
Avg. Vol
118,385
52-wk High
131.60kr
52-wk Low
82.80kr

Chart for

About

Recipharm publ AB is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). It is divided in two business areas: Manufacturing Services, supplying a range of pharmaceutical products in different dosage forms, such as solid dose, semi solids, beta-lactams, hormones, dry... (more)

Overall

Beta: 1.59
Market Cap(Mil.): kr4,464.81
Shares Outstanding(Mil.): 47.62
Dividend: 1.50
Yield (%): 1.60

Financials

  RECIb.ST Industry Sector
P/E (TTM): 38.61 30.95 32.75
EPS (TTM): 2.43 -- --
ROI: 1.87 14.84 14.38
ROE: 3.30 16.34 16.07

BRIEF-Recipharm Q1 EBITDA Up At SEK 250 Million

* Q1 NET SALES SEK 1.51 BILLION VERSUS SEK 1.33 BILLION YEAR AGO

27 Apr 2018

BRIEF-Recipharm Signs Licensing Agreement with Altus Formulation

* RECIPHARM AND ALTUS FORMULATION COLLABORATE TO OFFER NOVEL DRUG DELIVERY TECHNOLOGIES FOR VALUE ADDED MEDICINES

05 Mar 2018

BRIEF-Recipharm CFO Resigns

* ‍HENRIK STENQVIST WILL SERVE AS CFO UNTIL LATER IN SPRING.​

26 Feb 2018

BRIEF-Recipharm Q4 EBITDA At SEK 226 Million

* Q4 NET SALES SEK 1.40 BILLION VERSUS SEK 1.33 BILLION YEAR AGO

22 Feb 2018

BRIEF-Recipharm Buys Remaining Shares In Nitin Lifesciences

* RECIPHARM ACQUIRES REMAINING SHARES IN NITIN LIFESCIENCES LTD

02 Jan 2018

BRIEF-Recipharm commences new supply contract

* RECIPHARM COMMENCES NEW SUPPLY CONTRACT AND COMPLETES PURCHASE OF FACILITY IN SPAIN Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)

01 Dec 2017

BRIEF-Recipharm equips a further three facilities for U.S serialisation

* RECIPHARM EQUIPS A FURTHER THREE FACILITIES FOR US SERIALISATION Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

27 Nov 2017

Earnings vs. Estimates